← Back to patent-cliff list
CAS 3034-94-4
1-ethynyl-3-nitrobenzene
Codes: ICOT-025
Application context (from source-drug indications)
Non-small cell lung cancerIcotinib HydrochlorideLung adenocarcinomaIcotinib HydrochlorideBronchial neoplasmIcotinib HydrochlorideLung cancerIcotinib HydrochlorideMetastatic breast cancerIcotinib HydrochloridePsoriasisIcotinib Hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Icotinib Hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
3-ethynylaniline→(E)-3-(3-nitrophenyl)acrylic acid→(2S,3R)-2,3-dibromo-3-(3-nitrophenyl)propanoic acid→1-ethynyl-3-nitrobenzene
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.